ONO-3310 Study for Kidney Disease and Type 2 Diabetes
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This early-stage trial tests a new drug called ONO-3310 in two groups: healthy adults and people with kidney disease caused by type 2 diabetes. The study aims to understand how the drug works and whether it might help protect kidney function in people with diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male, 18–45 years old (healthy group) or 18–64 years old (kidney disease group)
- For kidney disease group only: You have type 2 diabetes with protein in your urine (measured by a 24-hour urine test)
- You do not have type 1 diabetes, severe liver or heart disease, or ongoing dialysis treatment
- You have no history of serious drug or food allergies, or drug or alcohol dependence
- For healthy group: Your BMI (weight-to-height ratio) is between 18.5 and 25.0
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called OJR520 to see if it's safe and how the body processes it. It first tests healthy volunteers and then people with chronic kidney disease to understand the drug's effects.
This trial tests an experimental drug called AZD4248 to see if it's safe for healthy people and for people with chronic kidney disease and type 2 diabetes. It also checks if a home device can accurately measure kidney function.
This study tests a new drug called IGT-303 for people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and can help protect kidney function.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
Hear when a new Type2 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.